News & Disclosures

Official press releases, regulatory notifications, financial announcements, and corporate disclosures from VVT Med Inc. All material information is filed on SEDAR+ as required by applicable securities law.

Filter:
Commercial

VVT Med Establishes Exclusive Canadian Commercial Partnership with CHS for ScleroSafe®

VVT Med signed a five-year exclusive distribution agreement, dated September 30, 2026, with Canadian Hospital Specialties (CHS), a Canadian medical technology organization founded in 1967 operating four distribution centres that can reach approximately 84% of Canadian customers within 48 hours. The long-term collaboration includes annual growth plans, physician education, and clinical and market development support, with effectiveness contingent on Health Canada regulatory authorization.

Full Article on Yahoo Finance
Financial

VVT Med Closes Second Tranche of Private Placement of Units; Over $1.8M in Total Proceeds Raised

VVT Med closed the second tranche of its non-brokered private placement, bringing total proceeds across both tranches to $1,885,103.50 from 7,540,414 units at $0.25 each. Each unit comprises one common share and half a warrant exercisable at $0.375 for 24 months. A third tranche is expected by the end of September 2026, and the company closed a concurrent debt settlement of $212,939.76 into 741,096 common shares.

Full Release on Newswire
Commercial

VVT Med Advances Portugal Market Entry as Dermworks Begins ScleroSafe® Market Evaluation and Announces Corporate Updates

VVT Med appointed Dermworks as exclusive trial distributor for ScleroSafe® in Portugal, building on earlier independent physician evaluations reporting immediate vein closure. The company also provided a financing update on its non-brokered private placement and announced a new marketing engagement with CEO.CA Technologies.

Full Article on TradingView
Corporate

VVT Med Announces Debt Settlement and Equity Incentive Grants to Strengthen Capital Structure

VVT Med agreed to settle $212,939.76 in vendor debt through the issuance of 741,096 common shares (280,000 at a deemed price of $0.25 and 461,096 at $0.31), subject to TSX Venture Exchange approval and a four-month statutory hold. The company also granted 688,773 stock options and 912,519 Restricted Share Units to directors, employees, and advisory board members, and confirmed the British Columbia Securities Commission revoked its management cease trade order on July 2, 2026.

Full Article on Yahoo Finance
Commercial

VVT Med Expands into the Dominican Republic, Appointing Antilles Medical as Exclusive Distributor

VVT Med established a Trial Distribution and Evaluation Agreement with Antilles Medical as exclusive distributor of ScleroSafe™ in the Dominican Republic, with an initial purchase order and a structured pathway toward a five-year partnership. The company also announced plans to close a second tranche of its private placement on or about July 20, 2026, with proceeds directed toward expanded global commercialization.

Full Release on GlobeNewswire
Regulatory

VVT Med Announces Positive Clinical Data for ScleroSafe® Published in Peer-Reviewed Indian Journal of Vascular and Endovascular Surgery

Peer-reviewed results show the ScleroSafe catheter-directed sclerotherapy system achieved 95% vein occlusion at 30 days with no serious adverse events across 30 patients at Holy Spirit Hospital in Mumbai. The publication validates the technology's efficacy as a non-thermal, non-tumescent treatment for varicose veins.

Full Release on GlobeNewswire
Commercial

VVT Med Signs Largest European Distribution Agreement to Date; Distributor Joins as Investor

VVT Med secured an exclusive five-year distribution partnership with Uber Ros S.p.A. covering Italy, Vatican City, and San Marino, representing approximately CAD $2.3 million in minimum purchase commitments. The distributor also joined the company's private placement financing, demonstrating strategic confidence in VVT Med's NT-NT technology platform.

Full Release on GlobeNewswire
Disclosure Notice: All material news affecting the Company is filed as a news release on SEDAR+ and disseminated to newswire services in accordance with TSXV continuous disclosure requirements. The list above may not be exhaustive; search SEDAR+ for the complete disclosure record.